Market Place
Sourcing Support
JAMA Study Shows Income Disparities In Type 2 Diabetes Outcomes
12 Dec 2024 //
BUSINESSWIRE
TheracosBio Sponsors Inaugural ADEPT Conference on Diabetes Equity
12 Nov 2024 //
BUSINESSWIRE
TheracosBio Partners To Provide Affordable Diabetes Medication
17 Oct 2024 //
BUSINESSWIRE
TheracosBio, PBA Partner For Affordable Diabetes Drug Access
03 Oct 2024 //
BUSINESSWIRE
BRENZAVVY Remains Lowest Priced SGLT2 Inhibitor Post IRA
28 Aug 2024 //
BUSINESSWIRE
TheracosBio`s BRENZAVVY® Non-Inferior To Dapagliflozin
12 Apr 2024 //
BUSINESSWIRE
TheracosBio Extends Partnership with Mark Cuban Cost Plus Drug Company
14 Feb 2024 //
BUSINESSWIRE
IPC Secures Distribution Rights to Independent Retail Pharmacies for BRENZAVVY
01 Feb 2024 //
PR NEWSWIRE
TheracosBio, IPC Announce Partnership to Make BRENZAVVY Available
20 Dec 2023 //
BUSINESSWIRE
TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty
22 Aug 2023 //
BUSINESSWIRE
TheracosBio and SmithRx Collaborate to Offer Approved Diabetes Drug Brenzavvy
17 Aug 2023 //
BUSINESSWIRE
TheracosBio Announces Publication of Data on the Safety of Brenzavvy
04 Aug 2023 //
BUSINESSWIRE
TheracosBio Appoints Brian Connelly as Chief Executive Officer
01 Aug 2023 //
BUSINESSWIRE
TheracosBio brings on Connelly to replace Collinson as CEO
01 Aug 2023 //
FIERCE PHARMA
TheracosBio, Cuban`s Cost Plus team up to launch new SGLT2 drug
13 Jul 2023 //
FIERCE PHARMA
TheracosBio Announces Commercial Availability of Brenzavvy
13 Jul 2023 //
BUSINESSWIRE
TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors
13 Mar 2023 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.